Molecular Diagnostics Markets, 2018-2019 & 2028 - Focus on PCR, FISH, PNA, Electrochemical Detection of DNA, Sequencing, Mitochondrial DNA, Biochips, Nanotechnology and Proteomic Technologies
DUBLIN, May 23, 2019 /PRNewswire/ -- The "Molecular Diagnostics - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
This report describes and evaluates the molecular diagnostics technologies that will play an important role in the practice of medicine, public health, pharmaceutical industry, forensics and biological warfare in the 21st century. This includes several polymerase chain reaction (PCR)-based technologies, fluorescent in situ hybridization (FISH), peptide nucleic acids (PNA), electrochemical detection of DNA, sequencing, mitochondrial DNA, biochips, nanotechnology and proteomic technologies.
Initial applications of molecular diagnostics were mostly for infections but are now increasing in the areas of genetic disorders, preimplantation screening and cancer. Genetic screening tests, despite some restrictions, is a promising area for future expansion of in vitro diagnostic market. Molecular diagnostics is being combined with therapeutics and forms an important component of integrated healthcare. Molecular diagnostic technologies are also involved in the development of personalized medicine based on pharmacogenetics and pharmacogenomics. Currently, there has been a considerable interest in developing rapid diagnostic methods for point-of-care and biowarfare agents such as anthrax.
The number of companies involved in molecular diagnostics has increased remarkably during the past few years. More than 1,000 companies have been identified to be involved in developing molecular diagnostics and 269 of these are profiled in the report along with tabulation of 661 collaborations. Despite the strict regulation, most of the development in molecular diagnostics has taken place in the United States, which has the largest number of companies.
The markets for molecular diagnostics technologies are difficult to estimate. Molecular diagnostics markets overlap with markets for non-molecular diagnostic technologies in the in vitro diagnostic market and are less well defined than those for pharmaceuticals. Molecular diagnostic markets are analyzed for 2018 according to technologies, applications and geographical regions. Forecasts are made up to 2028. A major portion of the molecular diagnostic market can be attributed to advances in genomics and proteomics. Biochip and nanobiotechnology are expected to make a significant contribution to the growth of molecular diagnostics.
Benefits of this report
-- This report has evolved during the past 24 years, profiting from
feedback by numerous readers and experts.
-- The most comprehensive and up-to-date one-stop source of information on
technical and commercial aspects of molecular diagnostics.
-- Includes profiles of 269 companies, the largest number in any report on
this topic.
-- 500 references, cited in the report are included in the bibliography.
-- The text is supplemented by 101 tables and 16 figures.
Who should read this report?
-- Chief executive officers of molecular diagnostic companies.
-- Business development executives of pharmaceutical and biotechnology
companies.
-- Executives of companies involved in developing the integration of
diagnosis and treatment as well as those interested in personalized
medicine.
-- Officers of genomic and proteomic companies interested in diagnostic
technologies.
-- Research scientists involved in application of molecular diagnostic
technologies.
-- Planners of healthcare services.
Key Topics Covered:
Part I: Technologies & Applications
Executive Summary
1. Introduction
2. Molecular Diagnostic Technologies
3 DNA dendrimer signal amplification
3. Biochips, Biosensors, and Nanobiotechnology
4. Proteomic Technologies for Molecular Diagnostics
5. Molecular Diagnosis of Genetic Disorders
6. Molecular diagnosis of cardiovascular disorders
7. Molecular Diagnosis of Infections
8. Molecular Diagnosis of Cancer
9. Molecular Diagnostics in Biopharmaceutical Industry & Healthcare
10. Molecular Diagnostics in Forensic Medicine and Biological Warfare
11. References
Part II: Regulations, Markets & Companies
12. Ethics, Patents and Regulatory issues
13. Markets for Molecular Diagnostics
14. Companies involved in molecular diagnostics
For more information about this report visit https://www.researchandmarkets.com/r/qer3i6
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
